TABLE 1.
Patient Characteristics (n = 40)
| Characteristic | Data |
|---|---|
| M:F ratio | 5.7:1 |
| Age at diagnosis (y) | 65 (37–81) |
| Primary diagnostic investigations | |
| Histopathology | 20 (50) |
| Imaging | 31 (77.5) |
| α-fetoprotein level | 19 (47.5) |
| Comorbidities | |
| Cirrhosis | 28 (70) |
| Hepatitis B or C | 18 (45) |
| Diabetes | 11 (27.5) |
| Nonalcoholic steatohepatitis/steatosis | 5 (12.5) |
| Portal vein thrombosis or invasion | 9 (22.5) |
| Ascites | |
| None | 29 (72.5) |
| Controlled | 10 (25) |
| Refractory | 1 (2.5) |
| Baseline investigations | |
| Body mass index (kg/m2) | 27.4 (20.2–38.5) |
| α-fetoprotein (ng/mL) | 36.1 (1–19,078) |
| Total bilirubin (μmol/L) | 0.8 (0.2–6.7) |
| Albumin (g/L) | 4.1 (2.6–5) |
| International normalized ratio | 1.1 (1–1.6) |
| Alkaline phosphatase (IU/L) | 127 (33–937) |
| Child–Pugh score | 5 (5–9) |
| Class A | 33 (82.5) |
| Class B | 7 (17.5) |
| Treatment received before PSMA PET/CT | |
| None | 27 (67.5) |
| Systemic treatment | 2 (5) |
| Surgery | 6 (15) |
| TACE or radiofrequency ablation | 14 (35) |
| SIRT | 4 (10) |
Qualitative data are number and percentage; continuous data are median and range.